NCT04655586 - Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

December 6, 2021

Study Completion Date

March 7, 2022

Conditions

Covid19

Interventions

DRUG

rNAPc2

two dose levels of rNAPc2

DRUG

Heparin

standard of care heparin per institution (therapeutic or prophylactic regimen)

Trial Locations (24)

22042

ARCA Investigational Site #105, Falls Church

23230

ARCA Investigational Site #114, Richmond

32209

ARCA Investigational Site #101, Jacksonville

36532

ARCA Investigational Site #119, Fairhope

60201

ARCA Investigational Site #128, Evanston

70121

ARCA Investigational Site #113, New Orleans

80045

ARCA Investigational Site #104, Aurora

80204

ARCA Investigational Site #117, Denver

85006

ARCA Investigational Site #118, Phoenix

85724

ARCA Investigational Site #120, Tucson

98405

ARCA Investigational Site #103, Tacoma

Unknown

ARCA Investigational Site #127, San Nicolás de los Arroyos

ARCA Investigational Site #130, Rosario

ARCA Investigational Site #112, Rosario

ARCA Investigational Site #111, Buenos Aires

ARCA Investigational Site #115, CABA

ARCA Investigational Site #126, Córdoba

ARCA Investigational Site #106, San Miguel de Tucumán

ARCA Investigational Site #129, San Miguel de Tucumán

ARCA Investigational Site #125, Campo Grande

ARCA Investigational Site #124, Bragança Paulista

ARCA Investigational Site #122, São José do Rio Preto

ARCA Investigational Site #123, Porto Alegre

ARCA Investigational Site #121, São Paulo